Judges Scientific PLC (GB:JDG)
LSE:JDG
Want to see GB:JDG full AI Analyst Report?
Top Page
Judges Scientific
(LSE:JDG)
Select Model
Select Model
Rating:57Neutral
Price Target:
4,461.00 p
â–¼(-0.31% Downside)
Action:ReiteratedDate:04/09/26
The score is driven primarily by solid financial performance (revenue growth and positive cash flow), tempered by weaker 2025 profitability and moderate leverage. Technicals are mixed-to-weak with the price below key longer-term moving averages and a negative MACD, and valuation is constrained by a relatively high P/E despite a moderate dividend yield.
Positive Factors
Sustained revenue growth
Multi-year revenue expansion nearly doubled sales from 2020–2025, reflecting durable demand across specialist instrument niches. Strong top-line momentum supports scale, R&D investment and distributor leverage, improving the structural capacity to generate profits and reinvest over the medium term.
Negative Factors
Moderate leverage
Material debt levels versus equity constrain financial flexibility and increase sensitivity to interest costs. For an acquisitive group, elevated leverage limits optionality for bolt-on deals or weathering cyclical revenue dips without higher refinancing or covenant risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained revenue growth
Multi-year revenue expansion nearly doubled sales from 2020–2025, reflecting durable demand across specialist instrument niches. Strong top-line momentum supports scale, R&D investment and distributor leverage, improving the structural capacity to generate profits and reinvest over the medium term.
Read all positive factors
Judges Scientific (JDG) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£315.04M
Dividend Yield1.89%
Average Volume (3M)19.94K
Price to Earnings (P/E)135.4
Beta (1Y)0.83
Revenue Growth9.13%
EPS Growth-47.18%
CountryUK
Employees767
SectorTechnology
Sector Strength88
IndustryHardware, Equipment & Parts
Share Statistics
EPS (TTM)0.10
Shares Outstanding6,660,444
10 Day Avg. Volume25,550
30 Day Avg. Volume19,941
Financial Highlights & Ratios
PEG Ratio-1.46
Price to Book (P/B)4.53
Price to Sales (P/S)2.60
P/FCF Ratio18.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£4,807.50Price Target Upside7.43% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)2.02
Revenue Forecast (FY)£127.68M
Judges Scientific Business Overview & Revenue Model
Company Description
Judges Scientific plc designs, manufactures, and sells scientific instruments. The company operates through two segments, Materials Sciences and Vacuum. It offers engineering teaching and research equipment for universities, colleges, schools, and...
How the Company Makes Money
Judges Scientific makes money primarily by selling specialized scientific instruments and systems through its operating subsidiaries. Its core revenue stream is product revenue from designing and manufacturing high-value, low-volume instruments ta...
Judges Scientific Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
58
Neutral
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 145.80M | 133.60M | 136.10M | 113.21M | 91.29M |
| Gross Profit | 12.70M | 92.00M | 93.60M | 21.01M | 15.34M |
| EBITDA | 32.10M | 30.90M | 32.20M | 29.00M | 20.33M |
| Net Income | 5.50M | 10.40M | 9.50M | 12.50M | 12.68M |
Balance Sheet | |||||
| Total Assets | 188.10M | 205.10M | 183.50M | 185.79M | 88.98M |
| Cash, Cash Equivalents and Short-Term Investments | 19.40M | 17.90M | 13.70M | 20.83M | 18.41M |
| Total Debt | 65.20M | 73.60M | 65.30M | 59.95M | 21.32M |
| Total Liabilities | 104.20M | 117.90M | 100.90M | 131.33M | 45.58M |
| Stockholders Equity | 83.70M | 86.90M | 82.40M | 54.24M | 42.78M |
Cash Flow | |||||
| Free Cash Flow | 21.00M | 22.10M | 20.60M | 12.33M | 13.44M |
| Operating Cash Flow | 26.40M | 28.50M | 26.50M | 20.22M | 16.89M |
| Investing Cash Flow | -7.40M | -22.60M | -25.90M | -50.80M | -5.21M |
| Financing Cash Flow | -17.40M | -1.40M | -7.60M | 31.20M | -8.81M |
Judges Scientific Technical Analysis
Positive
4475.00
Price Trends
4440.90
Positive
4977.25
Negative
5636.13
Negative
Market Momentum
0.61
Negative
57.56
Neutral
75.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:JDG, the sentiment is Positive. The current price of 4475 is above the 20-day moving average (MA) of 4177.75, above the 50-day MA of 4440.90, and below the 200-day MA of 5636.13, indicating a neutral trend. The MACD of 0.61 indicates Negative momentum. The RSI at 57.56 is Neutral, neither overbought nor oversold. The STOCH value of 75.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:JDG.
Judges Scientific Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | £623.83M | 10.73 | 8.34% | 2.09% | 0.49% | 61.73% | |
73 Outperform | £73.37M | 3.57 | 22.93% | ― | 136.76% | ― | |
72 Outperform | £3.37B | 17.58 | 8.06% | 2.12% | 4.99% | -24.08% | |
67 Neutral | £234.84M | 25.56 | 3.10% | 2.19% | 10.66% | 23.08% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
57 Neutral | £315.04M | 135.40 | 12.26% | 1.89% | 9.13% | -47.18% | |
54 Neutral | £212.27M | -4.02 | -31.21% | ― | -7.62% | 5.48% |
* Technology Sector Average
GB:JDG
Judges Scientific
4,700.00
-1,173.10
-19.97%
GB:GHH
Gooch & Housego
832.00
465.47
126.99%
GB:KMK
Kromek Group plc
11.30
6.20
121.57%
GB:RSW
Renishaw
4,616.00
2,383.63
106.78%
GB:TTG
TT Electronics
117.40
43.30
58.43%
GB:DSCV
discoverIE Group plc
643.00
86.21
15.48%
Judges Scientific Corporate Events
Business Operations and StrategyExecutive/Board Changes
Judges Scientific directors receive further shares under incentive plan
Neutral
Apr 9, 2026
Judges Scientific has disclosed a series of small share purchases in its ordinary shares on the London Stock Exchange’s AIM market, made on 7 April 2026 at 4,280p per share under its Share Incentive Plan. The transactions involve the trustee...
Other
Judges Scientific CEO Increases Stake with Share Purchase
Positive
Apr 7, 2026
Judges Scientific plc reported that its chief executive officer, Tim Prestidge, has purchased 641 ordinary shares in the company at 4,335 pence per share. Following the transaction, Prestidge’s beneficial holding stands at 1,248 ordinary sha...
Regulatory Filings and Compliance
Judges Scientific CFO Maintains Stake After Bed and ISA Share Reorganisation
Neutral
Apr 2, 2026
Judges Scientific plc reported that Chief Financial Officer Brad Ormsby and his spouse executed a “Bed and ISA” transaction involving 753 ordinary shares on 2 April, selling the shares at 4,300p apiece and immediately repurchasing an e...
Other
Judges Scientific Chair Gifts Shares to Charitable Trust, Retains Strong Stake
Neutral
Apr 2, 2026
Judges Scientific plc reported that Non-Executive Chair David Cicurel has transferred the beneficial interest in 4,000 ordinary shares to the Shoftim Charitable Trust, of which he is a trustee. Following the gift, Cicurel remains beneficially inte...
Business Operations and StrategyExecutive/Board ChangesDividendsFinancial DisclosuresM&A Transactions
Judges Scientific Lifts Dividend Despite US Funding Shock and Weak Orders
Neutral
Mar 31, 2026
Judges Scientific reported a challenging 2025 as uncertainties over US federal funding for scientific research and weaker offshore wind investment hit order intake and profitability, despite a 9.1% rise in revenue to £145.8m and broadly flat ...
Business Operations and StrategyFinancial Disclosures
Judges Scientific Schedules Investor Webinar on 2025 Results
Neutral
Mar 25, 2026
Judges Scientific will host an online investor presentation on 31 March at 5:00 p.m. U.K. time to discuss its results for the year ended 31 December 2025, open to both existing and potential shareholders. The event, led by the CEO, CFO, and Group ...
Business Operations and StrategyExecutive/Board Changes
Judges Scientific Executives Receive Shares Under Incentive Plan
Positive
Mar 10, 2026
Judges Scientific has reported a series of small share purchases in its ordinary stock made on 5 March 2026 by the trustees of its Share Incentive Plan on behalf of several senior executives and directors. The transactions, all executed on AIM at ...
Other
Judges Scientific Reports Routine Executive Share Incentive Plan Purchases
Neutral
Feb 9, 2026
Judges Scientific has disclosed a series of small share purchases made on 5 February 2026 for several senior executives under its Share Incentive Plan. Ordinary shares at 5,040p each were acquired on behalf of CEO David Cicurel, CFO Bradley Ormsby...
Regulatory Filings and Compliance
Judges Scientific Updates Total Voting Rights to 6.66 Million Shares
Neutral
Feb 2, 2026
Judges Scientific plc has reported that its total issued share capital stood at 6,660,444 ordinary shares of 5p each as of 31 January 2026, with no shares held in treasury and each share carrying one voting right. This updated figure, which establ...
Regulatory Filings and Compliance
Judges Scientific CEO Exercises Share Options, Lifting Issued Share Capital and Voting Rights
Neutral
Jan 29, 2026
Judges Scientific plc has announced that its Chief Executive Officer, David Cicurel, has exercised options over 7,500 new ordinary shares, increasing his beneficial holding to 551,892 shares and his combined beneficial and non-beneficial interest ...
Business Operations and StrategyExecutive/Board Changes
Judges Scientific Grants New Share Options Tied to Earnings Growth Targets
Positive
Jan 29, 2026
Judges Scientific has granted options over 81,600 new ordinary shares under its 2025 share option schemes at an exercise price of £52.00, largely to its executive directors, as part of its policy to use equity incentives for retention and per...
Business Operations and StrategyFinancial Disclosures
Judges Scientific Cuts Earnings Expectations as US Funding and Offshore Wind Slow Demand
Negative
Jan 22, 2026
Judges Scientific has warned that trading in 2025 fell short of expectations, as uncertainty over US federal funding for scientific research and weaker demand from offshore wind hit order intake and earnings, particularly in the United States wher...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.